Persson U, Tennvall G R, Andersson S, Tyden G, Wettermark B
The Swedish Institute for Health Economics (IHE), Lund, Sweden.
Pharmacoeconomics. 1992 Dec;2(6):500-8. doi: 10.2165/00019053-199202060-00008.
Economic appraisal of pharmaceuticals is becoming increasingly important. In a retrospective study of patient records from 58 organ or bone marrow-transplanted patients with systemic mycoses, the cost-effectiveness of treatment with a liposomal amphotericin B formulation was compared with that of conventional amphotericin B. Treatment with liposomal amphotericin B results in fewer adverse reactions, increased life expectancy and higher costs than treatment with conventional amphotericin B. Pricing liposomal amphotericin B at about SKE6000 per patient treatment day will result in an additional cost per life-year gained of about SEK150 000 relative to that using conventional amphotericin B for patients receiving kidney, kidney and pancreas, or pancreas transplants. For liver and bone marrow transplant (BMT) recipients the marginal cost-effectiveness ratio was about SEK195 000 and SEK150 000 per life-year gained. Compared with alternative use of resources in society and health care, use of liposomal amphotericin B rather than conventional amphotericin treatment can be considered cost-effective at the price assumed.
药物的经济评估正变得越来越重要。在一项对58例患有系统性真菌病的器官或骨髓移植患者的病历进行的回顾性研究中，比较了脂质体两性霉素B制剂治疗与传统两性霉素B治疗的成本效益。与传统两性霉素B治疗相比，脂质体两性霉素B治疗导致的不良反应更少、预期寿命延长且成本更高。对于接受肾脏、肾脏和胰腺或胰腺移植的患者，将脂质体两性霉素B定价为每名患者治疗日约6000瑞典克朗，相对于使用传统两性霉素B，每获得一个生命年的额外成本约为150000瑞典克朗。对于肝脏和骨髓移植（BMT）受者，每获得一个生命年的边际成本效益比约为195000瑞典克朗和150000瑞典克朗。与社会和医疗保健中资源的其他使用方式相比，以假定的价格使用脂质体两性霉素B而非传统两性霉素治疗可被认为具有成本效益。
